Neonatal Sepsis Market

Market Overview:

The 7 major neonatal sepsis markets are expected to exhibit a CAGR of 7.12% during 2024-2034.

The neonatal sepsis market has been comprehensively analyzed in IMARC's new report titled "Neonatal Sepsis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neonatal sepsis is a potentially life-threatening condition characterized by a systemic infection that occurs in newborn infants within the first month of life. It is primarily caused by bacteria, although other pathogens like viruses and fungi can also be responsible. The symptoms of the ailment can be subtle and nonspecific, making early diagnosis challenging. Common signs include fever, difficulty feeding, irritability, rapid breathing, lethargy, jaundice, and a change in skin color or temperature. Since these symptoms can overlap with several other newborn conditions, medical professionals must maintain a high index of suspicion when evaluating an infant for possible sepsis. The diagnosis of the ailment usually includes a combination of clinical evaluation, blood tests, and laboratory assessments. Blood cultures are crucial for identifying the specific pathogen responsible for the infection, while various other workups may reveal elevated white blood cell counts, abnormal levels of inflammatory markers, or signs of organ dysfunction.

The escalating incidences of numerous risk factors, such as premature birth, low birth weight, maternal infection during pregnancy, prolonged rupture of membranes, etc., are primarily driving the neonatal sepsis market. In addition to this, the inflating utilization of effective therapeutic approaches, including antibiotics, antiviral medications, and antifungal agents, for the prompt management and treatment of the disease is also creating a positive outlook for the market. Moreover, the widespread adoption of neonatal intensive care units (NICUs) equipped with advanced medical technologies and skilled healthcare professionals is further bolstering the market growth. These specialized units are instrumental in providing critical care and monitoring to neonates suffering from sepsis, thus ensuring timely intervention and improving clinical outcomes. Apart from this, the rising awareness and emphasis on preventive measures, such as maternal screening for infections during pregnancy, early detection of risk factors, and the promotion of breastfeeding, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of supportive therapies, including mechanical ventilation and fluid management, since they help in stabilizing the patient's physiological parameters and avert life-threatening scenarios like organ failure, is also augmenting the market growth. Furthermore, the increasing demand for immunotherapy, involving the use of immunoglobulins and cytokine inhibitors, to mitigate the severity of the condition is expected to drive the neonatal sepsis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the neonatal sepsis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for neonatal sepsis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neonatal sepsis market in any manner.

Recent Developments:

• In February 2024, the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) awarded GlyProVac $467k to develop a maternal vaccination targeting Escherichia coli (E. coli), a bacterial species that causes a significant part of neonatal sepsis infections. The CARB-X award supports the development of GlyProVac's maternal vaccine, GPV02, which uses a selected bacterial protein, naturally coated with tiny sugar molecules, to trigger an immune response for protection.

Key Highlights:

• Neonatal sepsis is classified into two types based on the time of manifestation after birth: early-onset sepsis (EOS) and late-onset sepsis (LOS).
• The incidence of EOS with positive blood cultures in the United States is estimated to be 0.77 to one per 1,000 live newborns.
• Males are at a higher risk of sepsis and meningitis, particularly with gram-negative enteric bacteria.
• According to the BARNARDS study, sepsis causes death in 2.5 million neonates or infants in their first month of life each year, with the biggest burden falling on low- and middle-income countries.
• The risk of death from neonatal sepsis increases by 7.6% every hour a treatment is delayed.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the neonatal sepsis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the neonatal sepsis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current neonatal sepsis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the neonatal sepsis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the neonatal sepsis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the neonatal sepsis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of neonatal sepsis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of neonatal sepsis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of neonatal sepsis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with neonatal sepsis across the seven major markets?
• What is the size of the neonatal sepsis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of neonatal sepsis?
• What will be the growth rate of patients across the seven major markets?
   

Neonatal Sepsis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for neonatal sepsis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neonatal sepsis market?
• What are the key regulatory events related to the neonatal sepsis market?
• What is the structure of clinical trial landscape by status related to the neonatal sepsis market?
• What is the structure of clinical trial landscape by phase related to the neonatal sepsis market?
• What is the structure of clinical trial landscape by route of administration related to the neonatal sepsis market?